PAVmed Inc. entered into subscription agreements for the private placement of 13,625 series A convertible preferred stock at an issue price of $1,000 per share for gross proceeds of $13,625,000 on March 7, 2023. The transaction included participation certain accredited investors. In connection with the offering the company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware.